PUMA BIOTECHNOLOGY, INC.
PBYIPuma Biotechnology is a publicly traded biopharmaceutical company (NASDAQ: PBYI) headquartered in Los Angeles, CA.
Drugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How PBYI's past catalysts played out
Neratinib
Advanced Breast Cancer
Temsirolimus
Breast Cancer
HKI-272
Carcinoma, Non-Small-Cell Lung
Alisertib
Hormone Receptor Positive HER-2 Negative Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Neratinib | Phase 3 | Advanced Breast Cancer | - | - |
Temsirolimus | Phase 2 | Breast Cancer | - | Patent 2032 |
HKI-272 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Alisertib | Phase 2 | Hormone Receptor Positive HER-2 Negative Breast Cancer | - | - |
Advanced Breast Cancer
1 drug in this indication
Breast Cancer
1 drug in this indication
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Hormone Receptor Positive HER-2 Negative Breast Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in PUMA BIOTECHNOLOGY, INC.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in PUMA BIOTECHNOLOGY, INC.'s (PBYI) pipeline across Phase 3, Phase 2. Its lead program is Neratinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PUMA BIOTECHNOLOGY, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for PUMA BIOTECHNOLOGY, INC. (PBYI) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track PBYI biotech catalysts?→
Add PBYI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PUMA BIOTECHNOLOGY, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.